PMID- 28526181
OWN - NLM
STAT- MEDLINE
DCOM- 20170703
LR  - 20191210
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 130
IP  - 6S
DP  - 2017 Jun
TI  - EMPA-REG OUTCOME: The Cardiologist's Point of View.
PG  - S57-S62
LID - S0002-9343(17)30459-X [pii]
LID - 10.1016/j.amjmed.2017.04.006 [doi]
AB  - Cardiologists could view empagliflozin as a cardiovascular drug that also has a 
      beneficial effect on reducing hyperglycemia in patients with type 2 diabetes 
      mellitus (T2DM). The effects of empagliflozin in lowering the risk of 
      cardiovascular death and hospitalization for heart failure in T2DM patients with 
      high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome 
      Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose 
      (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to 
      cardiovascular physiology; namely, by the potential ability of empagliflozin to 
      reduce cardiac workload and myocardial oxygen consumption by lowering blood 
      pressure, improving aortic compliance, and improving ventricular arterial 
      coupling. These concepts and hypotheses are discussed in this report.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Pham, Son V
AU  - Pham SV
AD  - The University of Texas Health Science Center, San Antonio, Tex.
FAU - Chilton, Robert
AU  - Chilton R
AD  - The University of Texas Health Science Center, San Antonio, Tex. Electronic 
      address: chilton@uthscsa.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cardiovascular Physiological Phenomena
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/physiopathology
MH  - Diabetic Angiopathies/*prevention & control
MH  - Glucosides/*therapeutic use
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Myocardium/metabolism
MH  - Oxygen Consumption
MH  - Risk Factors
MH  - Sodium-Glucose Transporter 2
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Ventricular Function, Left
OTO - NOTNLM
OT  - Cardiac workload
OT  - Cardiovascular outcomes
OT  - Empagliflozin
OT  - Myocardial oxygen consumption
OT  - Sodium glucose cotransporter 2 inhibitors
EDAT- 2017/05/21 06:00
MHDA- 2017/07/04 06:00
CRDT- 2017/05/21 06:00
PHST- 2017/05/21 06:00 [pubmed]
PHST- 2017/07/04 06:00 [medline]
PHST- 2017/05/21 06:00 [entrez]
AID - S0002-9343(17)30459-X [pii]
AID - 10.1016/j.amjmed.2017.04.006 [doi]
PST - ppublish
SO  - Am J Med. 2017 Jun;130(6S):S57-S62. doi: 10.1016/j.amjmed.2017.04.006.